



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Edward J. Kaplan

Serial No.: 10/665,793

Art Unit: Not Yet Assigned

Filed: September 19, 2003

Examiner: Not Yet Assigned

For: *FLEXIBLE AND/OR ELASTIC BRACHYTHERAPY SEED OR STRAND*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including thirteen (13) pages of Form PTO-1449 and copies of twenty-six (26) documents cited therein. Most of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/861,326, filed May 18, 2001, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however. Copies of the newly cited documents, which are identified with an asterisk (*), are enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

| <u>Number</u> | <u>Issue Date</u> | <u>Patentee</u> | <u>Class/Subclass</u> |
|---------------|-------------------|------------------|-----------------------|
| 3,993,073 | 11-23-1976 | Zaffaroni | 128/260 |
| 4,167,179 | 09-11-1979 | Kirsch | 128/1.2 |
| 4,351,337 | 09-28-1982 | Sidman | 128/260 |
| 4,427,005 | 01-24-1984 | Tener | 128/303 |
| 4,697,575 | 10-06-1987 | Horowitz | 128/1.2 |
| 4,700,692 | 10-20-1987 | Baumgartner | 128/1.2 |
| 4,706,652 | 11-17-1987 | Horowitz | 128/1.2 |
| 4,754,745 | 07-05-1988 | Horowitz | 128/1.2 |
| 4,763,642 | 08-16-1988 | Horowitz | 128/1.2 |
| 4,815,449 | 03-28-1989 | Horowitz | 600/7 |
| 4,820,844 | 04-11-1989 | Kagiya, et al. | 548/266 |
| 5,030,195 | 07-09-1991 | Nardi | 600/7 |
| 5,059,166 | 10-22-1991 | Fischell, et al. | 600/3 |
| 5,242,373 | 09-07-1993 | Scott, et al. | 600/7 |
| 5,342,283 | 08-30-1994 | Good | 600/8 |
| 5,424,288 | 06-13-1995 | Order | 514/2 |
| 5,460,592 | 10-24-1995 | Langton, et al. | 600/7 |
| 5,486,360 | 01-23-1996 | Ballagh, et al. | 524/94.4 |
| 5,538,726 | 07-23-1996 | Order | 424/178.1 |
| 5,595,979 | 01-21-1997 | Snyder | 514/49 |
| 5,620,700 | 04-15-1997 | Berggren | 424/435 |
| 5,626,829 | 05-06-1997 | Koutrouvelis | 424/1.11 |
| 5,626,862 | 05-06-1997 | Brem, et al. | 424/426 |
| 5,650,442 | 07-22-1997 | Mitchell, et al. | 514/611 |
| 5,871,437 | 02-16-1999 | Alt | 600/3 |
| 5,886,026 | 03-23-1999 | Hunter, et al. | 514/449 |
| 6,159,143 | 12-12-2000 | Lennox | 600/4 |
| 6,241,962 | 06-05-2001 | Nicolini, et al. | 424/1.61 |
| 6,248,057 | 06-19-2001 | Mavity, et al. | 600/3 |
| 6,391,279 | 05-21-2002 | Singh et al. | 424/1.29 |

U.S. Patent Applications

| <u>Number</u> | <u>Publication Date</u> | <u>Patentee</u> | <u>Class/Subclass</u> |
|---------------|-------------------------|-----------------|-----------------------|
| 2001/0044567 | 11-22-2001 | Zamora et al. | 600/3 |
| 2002/0055666 | 05-09-2002 | Hunter, et al. | 600/1 |
| 2002/0055667 | 05-09-2002 | Mavity et al. | 600/3 |
| 2003/0003094 | 01-02-2003 | Hunter, et al. | 424/94.63 |

Foreign Documents

| <u>Number</u> | <u>Publication Date</u> | <u>Patentee</u> | <u>Country</u> |
|---------------|-------------------------|---------------------------|----------------|
| WO 95/03036 | 02-02-1995 | Angiogenesis Technologies | PCT |
| WO 96/14880 | 05-23-1996 | PGK Corporation | PCT |
| WO 97/19706 | 06-05-1997 | IBT Technology Partners | PCT |
| WO 00/32238 | 06-08-2000 | Scimed Life Systems, Inc. | PCT |
| WO 00/41185 | 07-13-2000 | Nycomed Amersham PLC | PCT |
| WO 00/43045 | 07-27-2000 | Photogen, Inc. | PCT |
| WO 00/51639 | 09-08-2000 | Halogenetics, Inc. | PCT |
| WO 00/57923 | 10-05-2000 | North American Scientific | PCT |
| WO 01/36007 | 05-25-2001 | Angiotech Pharmaceuticals | PCT |
| WO 02/30472 | 04-18-2002 | Guilford Pharmaceuticals | PCT |

Publications

ALONSO, et al., "Biodegradable microspheres as controlled-release tetanus toxoid delivery systems," *Vaccine* 12: 299 (1994).

*ARCOS, et al., "Biphasic materials for bone grafting and hyperthermia treatment of cancer," *J. Biomed. Mater. Res.* 65: 71-78 (2003).

BEER, et al., "Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors," *Adv. Drug Deliv. Rev.* 27: 59 (1997).

BENZINA, et al., "Studies on a new radiopaque polymeric biomaterial," *Biomaterials* 15: 1122 (1994).

BREM, et al., "Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain," *J. Neurosurg.* 80: 283 (1994).

BREM, et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," *J. Neurosurg.* 74: 441 (1991).

BREM, et al., "Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas," *Lancet* 345: 1008 (1995).

*BOBOFCHAK, et al., "A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O₂ transporter," *Am. J. Physiol. Heart Circ. Physiol.* 285: H549-H561 (2003).

CAMARATA, et al., "Sustained release of nerve growth factor from biodegradable polymer microspheres," *Neurosurg.* 30: 313 (1992).

CARDINALE, et al., "Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice," *Radiation Oncol. Invest.* 6: 63 (1998).

CHATTARAJ, et al., "Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice," *J. Control. Rel.* 58: 223 (1999).

CHEN, et al., "Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization," *Drug Deliv.* 4: 301 (1997).

*CHU, et al., "Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent," *J. Ocular Pharm. Therapeut.* 18: 507-514 (2002).

CONFORTI, et al., "Anti-inflammatory activity of polyphosphazene-based naproxen slow-release systems," *J. Pharmacol.* 48: 468 (1996).

DASH & CUDWORTH II, "Therapeutic applications of implantable drug delivery systems," *JPM* 40: 1 (1998).

DOIRON, et al., "Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine," *Cancer Res.* 59(15): 3677-3681 (1999).

DOMB, et al., "Polyanhydrides I: Preparation of high molecular weight polymers," *J. Polym. Sci.* 25: 3373 (1987).

DURING, et al., "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," *Ann. Neurol.* 25: 351 (1989).

EWEND, et al., "Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models," *Research* 56: 5217 (1996).

FOWLER, et al., "Evaluation of an implant that delivers leuprolide for one year for the palliative treatment of prostate cancer," *Urology* 55: 639 (2000).

FUNG, et al., "Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain," *Cancer Res.* 58: 672 (1998).

*GANZA-GONZALEZ, et al., "Chitosan and chondroitin microspheres for oral-administration controlled release of metoclopramide," *Eur. J. Pharm. Biopharm.* 48: 149-155 (1999).

*GEIM, et al., "Microfabricated adhesive mimicking gecko foot-hair," *Nature Materials* 2: 461-463 (2003).

GOBIN, et al., "Embolization with radiopaque microbeads of polyacrylonitrile hydrogel: evaluation in swine," *Radiology* 214: 113 (2000).

GROSSMAN, et al., "The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers," *J. Neurosurg.* 76: 640 (1992).

HAFELI, et al., "Effective targeting of magnetic radioactive ⁹⁰Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results," *Nuclear Med. Biol.* 22: 147 (1995).

HARPER, et al., "Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice," *Clin. Canc. Res.* 5: 4242 (1999).

*HILGENFELDT, et al., "The acoustics of diagnostic microbubbles: dissipative effects and heat deposition," *Ultrasonics* 38: 99-104 (2000).

HORAK, et al., "New radiopaque polyHEMA-based hydrogel particles," *J. Biomed. Mat. Res.* 34: 183 (1997).

HORIUCHI, et al., "Radiotherapy for carcinoma of the tongue with special emphasis on advanced cases," *J. Jap. Soc. Cancer Ther.* 15(5): 851-857 (1980).

*JAISWAL, et al., "Long-term multiple color imaging of live cells using quantum dot bioconjugates," *Nature Biotechnol.* 21: 47-51 (2003).

JUDY, et al., "Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas," *J. Neurosurg.* 82: 481 (1995).

*KAKIZAKI, et al., "Lipidhememicrosphere (LH-M). A new type of totally synthetic oxygen carrier and its oxygen carrying ability," *Art. Cells Blood Substit. Immobil.* 22: 933-938 (1994).

KHARKEVICH, et al., "Employment of magnet-susceptible microparticles for the targeting of drugs," *J. Pharm. Pharmacol.* 41: 286 (1989).

KONG, et al., "Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumors in rats," *J. Surg. Oncol.* 69: 76 (1998).

KUBEK, et al., "Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation," *Brain Res.* 809: 189 (1998).

KUNOU, et al., "Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits," *J. Control. Rel.* 37: 143 (1995).

KURIAKOSE, et al., "Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/scid mouse model," *Head & Neck* p. 57 (2000).

LAURENCIN, et al., "Bioerodible polyanhydrides for antibiotic drug delivery: in vitro osteomyelitis treatment in a rat model system," *J. Orthopaedic Res.* 11: 256 (1993).

*LEBUGLE, et al., "Study of implantable calcium phosphate systems for the slow release of methotrexate," *Biomaterials* 23: 3517-3522 (2002).

LEIBEL & PHILLIPS, Textbook of Radiation Oncology (1998).

*LENDLEIN, et al., "Biodegradable, elastic shape-memory polymers for potential biomedical applications," *Science* 296: 1673-1676 (2002).

LESTER, et al., "Assessment of barium impregnated polyethylene spheres (BIPS®) as a measure of solid-phase gastric emptying in normal dogs – comparison to scintigraphy," *Vet. Radiol. Ultrasound* 40: 465 (1999).

LI, et al., "Biodistribution of cyclic carbonate of ioxilan: a radiopaque particulate macrophage imaging agent," *Acad. Radiol.* 3: 500 (1996).

*LIANG, et al., "Adhesion force measurements on single gecko setae," *Solid-State Sensor and Actuator Workshop* 33-38 (2000).

MAUER, et al., "Hepatic artery embolisation with a novel radiopaque polymer causes extended liver necrosis in pigs due to occlusion of the concomitant portal vein," *J. Hepatology* 32: 261 (2000).

MENEI, et al., "Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," *Cancer* 86: 325 (1999).

*MERRICK, et al., "Seed fixity in the prostate/periprostatic region following brachytherapy," *Int. J. Radiation Oncol. Biol. Phys.* 46: 215-220 (2000).

*MINAMIMURA, et al., "Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats," *Int. J. Oncol.* 16: 1153-1158 (2000).

*MITSUMORI, et al., "Development of intra-arterial hyperthermia using a dextran-magnetite complex," *Int. J. Hyperthermia* 10: 785-793 (1994).

MIYAMOTO, et al., "Biodegradable scleral implant for intravitreal controlled release of fluconazole," *Curr. Eye Res.* 16: 930 (1997).

MORITERA, et al., "Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy," *Invest. Ophthalmol. Vis. Sci.* 33: 3125 (1992).

*MOROZ, et al., "Arterial embolization hyperthermia in porcine renal tissue," *J. Surg. Res.* 105: 209-214 (2002).

PARK, et al., "Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation and kinetics and mechanism of in vitro release," *J. Control. Rel.* 52: 179 (1998).

PEREZ & BRADY, Principles and Practice of Radiation Oncology, 3rd ed, p. 54 (1998).

*PERKA, et al., "The use of fibrin beads for tissue engineering and subsequential transplantation," *Tiss. Eng.* 7: 359-361 (2001).

PHILIPPE, et al., "Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," *Cancer* 86: 325 (1999).

*POGGI, et al., "Marker and seed migration in prostate localization," *Int. J. Radiation Oncol. Biol. Phys.* 56: 1248-1251 (2003).

PRESTIDGE, et al., "Post-treatment biopsy results following permanent transrectal ultrasound-guided interstitial brachytherapy in early stage prostate cancer," *Int. J. Radiation Oncol. Biol. Phys.* 32(Suppl 1): 144 (1995).

QIAN, et al., "Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods," *J. Biomed. Mater. Res.* 55: 512 (2001).

RAMIREZ, et al., "Biodegradable poly(DL-lactic-co-glycolic acid) microspheres containing tetracaine hydrochloride. In-vitro release profile," *J. Microencapsulation* 16: 105 (1999).

REINHARD, et al., "Polymeric controlled release of dexamethasone in normal rat brain," *J. Control. Rel.* 16: 331 (1991).

RINGKJOB, "Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents," *Aeta Neurol. Scandinav.* 44: 318 (1968).

*ROBERTO, et al., "Structure and dosimetric analysis of biodegradable glasses for prostate cancer treatment," *Art. Organs* 27: 432-433 (2003).

SANCHEZ, et al., "In vivo study of the tissue distribution and immunosuppressive response of cyclosporin A-loaded polyester micro- and nanospheres," *Drug Deliv.* 2: 21 (1995).

*SCHEIBEL, et al., "Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition," *Proc. Natl. Acad. Sci.* 100: 4527-4532 (2003).

SEE, et al., "Brachytherapy and continuous infusion 5-fluorouracil for the treatment of locally advanced, lymph node negative, prostate cancer," *Cancer* 77(5): 924-927 (1996).

*SENDEROFF, et al., "Fibrin based drug delivery systems," *J. Parenter. Sci. Technol.* 45: 2-6 (1991).

*SIVAKUMAR, et al., "Preparation, characterization and in vitro release of gentamicin from coralline hydroxyapatite-gelatin composite microspheres," *Biomaterials* 23: 3175-3181 (2002).

STRAW, et al., "Effects of cis-diaminedichloroplatinum II released from D,L-poly(lactic acid) implanted adjacent to cortical allografts in dogs," *J. Orthopaedic Res.* 12: 871 (1994).

*SUNDBACK, et al., "Manufacture of porous polymer nerve conduits by a novel low-pressure injection molding process," *Biomaterials* 24: 819-830 (2003).

TAMARGO, et al., "Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate," *J. Neurooncol.* 9: 131 (1990).

TAMARGO, et al., "Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain," *Cancer Res.* 53: 329 (1993).

TAMARGO, et al., "Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema," *J. Neurosurg.* 74: 956 (1991).

*TAPEN, et al., "Reduction of radioactive seed embolization to the lung following prostate brachytherapy," *Biomater.* 24: 819-830 (2003).

THANOO & JAYAKRISHNAN, "Radiopaque hydrogel microspheres," *J. Microencapsulation* 6: 233 (1989).

THANOO, et al., "Tantalum-loaded polyurethane microspheres for particulate embolization: preparation and properties," *Biomaterials* 12: 525 (1991).

VALTONEN, et al., "Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study," *Neurosurg.* 41: 44 (1997).

*VIROONCHATAPAN, et al., "Preparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: an on-line flow system for quantifying magnetic responsiveness," *Pharm. Res.* 12: 1176-1183 (1995).

WALTER, et al., "Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma," *Cancer Res.* 54: 2207 (1994).

*WANG, et al., "A tough biodegradable elastomer," *Nature Biotechnol.* 20: 602-606 (2002).

WANG, et al., "Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma," *J. Nucl. Med.* 39: 1752 (1998).

WEI, et al., "Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization," *Drug Delivery* 4: 301 (1997).

WEINGART, et al., "Local delivery of dexamethasone in the brain for the reduction of peritumoral edema," *Int. J. Cancer* 62: 1 (1995).

WILLIAMS, et al., "Synthetic, implantable polymers for local delivery of IUDR to experimental human malignant glioma," *Int. J. Radiation Oncol. Biol. Phys.* 42: 631 (1998).

WUNDERLICH, et al., "Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy," *Appl. Radiation Isotopes* 52: 63 (2000).

YANG, et al., "Diagnostic and therapeutic potential of poly(benzyl L-glutamate)," *J. Pharm. Sci.* 83: 328 (1994).

YAPP, et al., "Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice," *Anti-Cancer Drugs* 9: 791 (1998).

YAPP, et al., "The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin," *Int. J. Radiation Oncol. Biol. Phys.* 42: 413 (1998).

YAPP, et al., "Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation," *Int. J. Radiation Oncol. Biol. Phys.* 39: 497 (1998).

YOSHIDA, et al., "In vivo release of cisplatin from a needle-type copolymer formulation implanted in rat kidney," *Biomaterials* 10: 17 (1989).


YUAN, et al., "Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma," *Radiation Oncol. Invest.* 7: 218 (1999).

*ZHANG, et al., "An all-organic actuator material with a high dielectric constant," *Nature* 419: 284-287 (2002).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Patrea L. Pabst', is written over a horizontal line.

Patrea L. Pabst
Reg. No. 31,284

Dated: December 23, 2003


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 10/665,793
Filed: September 19, 2003
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 23, 2003


Peggy Bailey

1469981_v1


Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|------------------------|--------------------------|--------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Applicant Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 1 of 13 | Attorney Docket Number | KAP 100 CIP | |

| U.S. PATENT DOCUMENTS | | | | | | |
|--|-----------------------|--------------------|--------------------------------------|---|--------------------------------------|---|
| Examiner Initials* | Cite No. ¹ | US Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| /JS/ | | 3,993,073 | | Zaffaroni | 11-23-1976 | |
|  | | 4,167,179 | | Kirsch | 09-11-1979 | |
| | | 4,351,337 | | Sidman | 09-28-1982 | |
| | | 4,427,005 | | Tener | 01-24-1984 | |
| | | 4,697,575 | | Horowitz | 10-06-1987 | |
| | | 4,700,692 | | Baumgartner | 10-20-1987 | |
| | | 4,706,652 | | Horowitz | 11-17-1987 | |
| | | 4,754,745 | | Horowitz | 07-05-1988 | |
| | | 4,763,642 | | Horowitz | 08-16-1988 | |
| | | 4,815,449 | | Horowitz | 03-28-1989 | |
| | | 4,820,844 | | Kagiya, et al. | 04-11-1989 | |
| | | 5,030,195 | | Nardi | 07-09-1991 | |
| | | 5,059,166 | | Fischell, et al. | 10-22-1991 | |
| | | 5,242,373 | | Scott, et al. | 09-07-1993 | |
| | /JS/ | | 5,342,283 | | Good | 08-30-1994 |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|---|-----------------------|-------------------------|---------------------|--------------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office. ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| /JS/ | | PCT | WO 95/03036 | | Angiogenesis Technologies | 02-02-1995 | | |
|  | | PCT | WO 96/14880 | | PGK Corporation | 05-23-1996 | | |
| | | PCT | WO 97/19706 | | IBT Technology Partners | 06-05-1997 | | |
| | | PCT | WO 00/32238 | | Scimed Life Systems, Inc. | 06-08-2000 | | |
| | | PCT | WO 00/41185 | | Nycomed Amersham PLC | 07-13-2000 | | |
| /JS/ | | PCT | WO 00/43045 | | Photogen, Inc. | 07-27-2000 | | |

| | | |
|-------------------|-----------------------------------|-----------------|
| Examine Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered |
|-------------------|-----------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | |
|--|----|----------------------|------------------------|-------------|
| Substitute for form 1449A/PTO | | Compleat If Kn wn | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)  | | Applicati n Number | 10/665,793 | |
| | | Filing Date | September 19, 2003 | |
| | | First Named Inventor | Edward J. Kaplan | |
| | | Group Art Unit | | |
| | | Examiner Name | | |
| Sheet | of | 13 | Attorney Docket Number | KAP 100 CIP |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|--------------------|-----------------------------------|---|-----------------------------------|---|
| Examiner Initials* | Cite No. ¹ | US Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| /JS/ | | 5,424,288 | | Order | 06-13-1995 | |
| | | 5,460,592 | | Langton, et al. | 10-24-1995 | |
| | | 5,486,360 | | Ballagh, et al. | 01-23-1996 | |
| | | 5,538,726 | | Order | 07-23-1996 | |
| | | 5,595,979 | | Snyder | 01-21-1997 | |
| | | 5,620,700 | | Berggren | 04-15-1997 | |
| | | 5,626,829 | | Koutrouvelis | 05-06-1997 | |
| | | 5,626,862 | | Brem, et al. | 05-06-1997 | |
| | | 5,650,442 | | Mitchell, et al. | 07-22-1997 | |
| | | 5,871,437 | | Alt | 02-16-1999 | |
| | | 5,886,026 | | Hunter, et al. | 03-23-1999 | |
| | | 6,159,143 | | Lennox | 12-12-2000 | |
| | | 6,241,962 | | Nicolini, et al. | 06-05-2001 | |
| | | 6,248,057 | | Mavity, et al. | 06-19-2001 | |
| /JS/ | | 6,391,279 | | Singh et al. | 05-21-2002 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁸ |
| | | Office. ³ | Number ² | Kind Code ⁵ (if known) | | | | |
| /JS/ | | PCT | WO 00/51639 | | Halogenetics, Inc. | 09-08-2000 | | |
| /JS/ | | PCT | WO 00/57923 | | North American Scientific | 10-05-2000 | | |
| /JS/ | | PCT | WO 01/36007 | | Angiotech Pharmaceuticals | 05-25-2001 | | |
| /JS/ | | PCT | WO 02/30472 | | Guilford Pharmaceuticals | 04-18-2002 | | |
| | | | | | | | | |
| | | | | | | | | |

| | | |
|-------------------|-----------------------------------|-----------------|
| Examine Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered |
|-------------------|-----------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|--|------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use as many sheets as necessary) | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | KAP 100 CIP |
| Sheet 4 of 13 | | | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | (1994) | ALONSO, et al., "Biodegradable microspheres as controlled-release tetanus toxoid delivery systems," <i>Vaccine</i> 12: 299 | |
| | (2003) | *ARCOS, et al., "Biphasic materials for bone grafting and hyperthermia treatment of cancer," <i>J. Biomed. Mater. Res.</i> 65: 71-78 (2003) | |
| | | BEER, et al., "Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors," <i>Adv. Drug Deliv. Rev.</i> 27: 59 (1997) | |
| | | BENZINA, et al., "Studies on a new radiopaque polymeric biomaterial," <i>Biomaterials</i> 15: 1122 (1994) | |
| | | BREM, et al., "Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain," <i>J. Neurosurg.</i> 80: 283 (1994) | |
| | | BREM, et al., "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," <i>J. Neurosurg.</i> 74: 441 (1991) | |
| | | BREM, et al., "Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas," <i>Lancet</i> 345: 1008 (1995) | |
| | | *BOBOFCHAK, et al., "A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O ₂ transporter," <i>Am. J. Physiol. Heart Circ. Physiol.</i> 285: H549-H566 (2003) | |
| | | CAMARATA, et al., "Sustained release of nerve growth factor from biodegradable polymer microspheres," <i>Neurosurg.</i> 30: 313 (1992) | |
| /JS/ | | CARDINALE, et al., "Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice," <i>Radiation Oncol. Invest.</i> 6: 63 (1998) | |

| | | |
|----------------------|-----------------------------------|-----------------|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered |
|----------------------|-----------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|----------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 5 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | CHATTARAJ, et al., "Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice," <i>J. Control. Rel.</i> 58: 223 (1999) | |
| | | CHEN, et al., "Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization," <i>Drug Deliv.</i> 4: 301 (1997). | |
| | | *CHU, et al., "Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent," <i>J. Ocular Pharm. Therapeut.</i> 18: 507-514 (2002). | |
| | | CONFORTI, et al., "Anti-inflammatory activity of polyphosphazene-based naproxen slow-release systems," <i>J. Pharmacol.</i> 48: 468 (1996). | |
| | | DASH & CUDWORTH II, "Therapeutic applications of implantable drug delivery systems," <i>JPM</i> 40: (1998). | |
| | | DOIRON, et al., "Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine," <i>Cancer Res.</i> 59(15): 3677-3681 (1999). | |
| | | DOMB, et al., "Polyanhydrides I: Preparation of high molecular weight polymers," <i>J. Polym. Sci.</i> 25: 3373 (1987). | |
| | | DURING, et al., "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," <i>Ann. Neurol.</i> 25: 351 (1989). | |
| | | EWEND, et al., "Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models," <i>Research</i> 56: 521 (1996). | |
| /JS/ | | FOWLER, et al., "Evaluation of an implant that delivers leuprolide for one year for the palliative treatment of prostate cancer," <i>Urology</i> 55: 639 (2000). | |

| | | | |
|----------------------|-----------------------------------|-----------------|--|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|-----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|------------------------|----------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary) | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 6 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | FUNG, et al., "Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain," <i>Cancer Res.</i> 58: 672 (1998) | |
| | | *GANZA-GONZALEZ, et al., "Chitosan and chondroitin microspheres for oral-administration controlled release of metoclopramide," <i>Eur. J. Pharm. Biopharm.</i> 48: 149-155 (1999) | |
| | | *GEIM, et al., "Microfabricated adhesive mimicking gecko foot-hair," <i>Nature Materials</i> 2: 461-463 (2003) | |
| | | GOBIN, et al., "Embolization with radiopaque microbeads of polyacrylonitrile hydrogel: evaluation in swine," <i>Radiology</i> 214: 113 (2000) | |
| | | GROSSMAN, et al., "The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers," <i>J. Neurosurg.</i> 76: 640 (1992) | |
| | | HAFELI, et al., "Effective targeting of magnetic radioactive ⁹⁰ Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results," <i>Nuclear Med. Biol.</i> 22: 147 (1995) | |
| | | HARPER, et al., "Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice," <i>Clin. Canc. Res.</i> 5: 4242 (1999) | |
| | | *HILGENFELDT, et al., "The acoustics of diagnostic microbubbles: dissipative effects and heat deposition," <i>Ultrasonics</i> 38: 99-104 (2000) | |
| | | HORAK, et al., "New radiopaque polyHEMA-based hydrogel particles," <i>J. Biomed. Mat. Res.</i> 34: 183 (1997) | |
| /JS/ | | HORIUCHI, et al., "Radiotherapy for carcinoma of the tongue with special emphasis on advanced cases," <i>J. Jap. Soc. Cancer Ther.</i> 15(5): 851-857 (1980) | |

| | | |
|----------------------|-----------------------------------|-----------------|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered |
|----------------------|-----------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|------------------------|----------------------|--------------------|
| Substitute for form 1449A/PTO | | Compl t If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary) | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 7 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | *JAISWAL, et al., "Long-term multiple color imaging of live cells using quantum dot bioconjugates," <i>Nature Biotechnol.</i> 21: 47-51 (2003). | |
| | | JUDY, et al., "Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas," <i>J. Neurosurg.</i> 82: 481 (1995). | |
| | | *KAKIZAKI, et al., "Lipidhememicrosphere (LH-M). A new type of totally synthetic oxygen carrier and its oxygen carrying ability," <i>Art. Cells Blood Substit. Immobil.</i> 22: 933-938 (1994). | |
| | | KHARKOVICH, et al., "Employment of magnet-susceptible microparticles for the targeting of drugs," <i>J. Pharm. Pharmacol.</i> 41: 288 (1989). | |
| | | KONG, et al., "Intracranially implanted cisplatin plus systemic carmustine for the treatment of brain tumors in rats," <i>J. Surg. Oncol.</i> 69: 76 (1998). | |
| | | KUBEK, et al., "Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation," <i>Brain Res.</i> 809: 189 (1998). | |
| | | KUNOU, et al., "Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits," <i>J. Control. Rel.</i> 37: 143 (1995). | |
| | | KURIAKOSE, et al., "Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/scid mouse model," <i>Head & Neck</i> p. 57 (2000). | |
| | | LAURENCIN, et al., "Bioerodible polyanhydrides for antibiotic drug delivery: in vitro osteomyelitis treatment in a rat model system," <i>J. Orthopaedic Res.</i> 11: 256 (1993). | |
| /JS/ | | *LEBUGLE, et al., "Study of implantable calcium phosphate systems for the slow release of methotrexate," <i>Biomaterials</i> 23: 3517-3522 (2002). | |

| | | | |
|----------------------|-----------------------------------|-----------------|--|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|-----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|-------|------------------------|--------------------|
| Substitute for form 1449A/PTO | | Completeness | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 2 of 8 | of 13 | Attorney Docket Number | KAP 100 CIP |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | LEIBEL & PHILLIPS, <u>Textbook of Radiation Oncology</u> (1998). | |
| | | *LENDLEIN, et al., "Biodegradable, elastic shape-memory polymers for potential biomedical applications," <i>Science</i> 296: 1673-1676 (2002). | |
| | | LESTER, et al., "Assessment of barium impregnated polyethylene spheres (BIPS®) as a measure of solid-phase gastric emptying in normal dogs – comparison to scintigraphy," <i>Vet. Radiol. Ultrasound</i> 40: 465 (1999). | |
| | | LI, et al., "Biodistribution of cyclic carbonate of ioxilan: a radiopaque particulate macrophage imaging agent," <i>Acad. Radiol.</i> 3: 500 (1996). | |
| | | *LIANG, et al., "Adhesion force measurements on single gecko setae," <i>Solid-State Sensor and Actuator Workshop</i> 33-38 (2000). | |
| | | MAUER, et al., "Hepatic artery embolisation with a novel radiopaque polymer causes extended liver necrosis in pigs due to occlusion of the concomitant portal vein," <i>J. Hepatology</i> 32: 26 (2000). | |
| | | MENEI, et al., "Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," <i>Cancer</i> 86: 325 (1999). | |
| | | *MERRICK, et al., "Seed fixity in the prostate/periprostatic region following brachytherapy," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 46: 215-220 (2000). | |
| | | *MINAMIMURA, et al., "Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats," <i>Int. J. Oncol.</i> 16: 1153-1158 (2000). | |
| /JS/ | | *MITSUMORI, et al., "Development of intra-arterial hyperthermia using a dextran-magnetite complex," <i>Int. J. Hyperthermia</i> 10: 785-793 (1994). | |

| | | | |
|----------------------|-----------------------------------|-----------------|--|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|-----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|--|------------------------|--------------------|
| Substitute for form 1449A/PTO | | Completeness | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | KAP 100 CIP |
| Sheet 9 of 13 | | | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | MIYAMOTO, et al., "Biodegradable scleral implant for intravitreal controlled release of fluconazole," <i>Curr. Eye Res.</i> 16: 930 (1997) | |
| | | MORITERA, et al., "Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy," <i>Invest. Ophthalmol. Vis. Sci.</i> 33: 3125 (1992) | |
| | | MOROZ, et al., "Arterial embolization hyperthermia in porcine renal tissue," <i>J. Surg. Res.</i> 105: 209-214 (2002) | |
| | | PARK, et al., "Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: preparation and kinetics and mechanism of in vitro release," <i>J. Control. Rel.</i> 52: 179 (1998) | |
| | | PEREZ & BRADY, <i>Principles and Practice of Radiation Oncology</i> , 3 rd ed, p. 54 (1998) | |
| | | PERKA, et al., "The use of fibrin beads for tissue engineering and subsequential transplantation," <i>Tiss. Eng.</i> 7: 359-361 (2001) | |
| | | PHILIPPE, et al., "Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma," <i>Cancer</i> 86: 325 (1999) | |
| | | POGGI, et al., "Marker and seed migration in prostate localization," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 56: 1248-1251 (2003) | |
| | | PRESTIDGE, et al., "Post-treatment biopsy results following permanent transrectal ultrasound-guided interstitial brachytherapy in early stage prostate cancer," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 32(Suppl 1): 14 (1995) | |
| /JS/ | | QIAN, et al., "Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods," <i>J. Biomed. Mater. Res.</i> 55: 512 (2001) | |

| | | |
|----------------------|-----------------------------------|-----------------|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered |
|----------------------|-----------------------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|----------------------|--------------------|
| Substitute for form 1449A/PTO | | Compleat If Kn wn | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  | | Applicati n Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 10 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | RAMIREZ, et al., "Biodegradable poly(DL-lactide-co-glycolic acid) microspheres containing tetracaine hydrochloride. In-vitro release profile," <i>J. Microencapsulation</i> 16: 105 (1999) | |
| | | REINHARD, et al., "Polymeric controlled release of dexamethasone in normal rat brain," <i>J. Control. Rel.</i> 16: 331 (1991) | |
| | | RINGKJOB, "Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents," <i>Aeta Neurol. Scandinav.</i> 44: 318 (1968) | |
| | | *ROBERTO, et al., "Structure and dosimetric analysis of biodegradable glasses for prostate cancer treatment," <i>Art. Organs</i> 27: 432-433 (2003) | |
| | | SANCHEZ, et al., "In vivo study of the tissue distribution and immunosuppressive response of cyclosporin A-loaded polyester micro- and nanospheres," <i>Drug Deliv.</i> 2: 21 (1995) | |
| | | *SCHEIBEL, et al., "Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition," <i>Proc. Natl. Acad. Sci.</i> 100: 4527-4533 (2003) | |
| | | SEE, et al., "Brachytherapy and continuous infusion 5-fluorouracil for the treatment of locall advanced, lymph node negative, prostate cancer," <i>Cancer</i> 77(5): 924-927 (1996) | |
| | | *SENDEROFF, et al., "Fibrin based drug delivery systems," <i>J. Parenter. Sci. Technol.</i> 45: 2-6 (1991) | |
| | | *SIVAKUMAR, et al., "Preparation, characterization and in-vitro release of gentamicin from coralline hydroxyapatite-gelatin composite microspheres," <i>Biomaterials</i> 23: 3175-3181 (2002) | |
| /JS/ | | STRAW, et al., "Effects of cis-diaminedichloroplatinum II released from D,L-poly(lactic acid implanted adjacent to cortical allografts in dogs," <i>J. Orthopaedic Res.</i> 12: 871 (1994) | |

| | | | |
|----------------------|-----------------------------------|-----------------|--|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|-----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|------------------------|----------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 11 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | *SUNDBACK, et al., "Manufacture of porous polymer nerve conduits by a novel low-pressure injection molding process," <i>Biomaterials</i> 24: 819-830 (2003) | |
| | | TAMARGO, et al., "Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate," <i>J. Neurooncol.</i> 9: 131 (1990) | |
| | | TAMARGO, et al., "Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain," <i>Cancer Res.</i> 53: 329 (1993) | |
| | | TAMARGO, et al., "Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema," <i>J. Neurosurg.</i> 74: 956 (1991) | |
| | | *TAPEN, et al., "Reduction of radioactive seed embolization to the lung following prostate brachytherapy," <i>Biomater.</i> 24: 819-830 (2003) | |
| | | THANOO & JAYAKRISHNAN, "Radiopaque hydrogel microspheres," <i>J. Microencapsulation</i> 6: 233 (1989) | |
| | | THANOO, et al., "Tantalum-loaded polyurethane microspheres for particulate embolization: preparation and properties," <i>Biomaterials</i> 12: 525 (1991) | |
| | | VALTONEN, et al., "Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study," <i>Neurosurg.</i> 41: 44 (1997) | |
| | | *VIROONCHATAPAN, et al., "Preparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: an on-line flow system for quantifying magnetic responsiveness," <i>Pharm. Res.</i> 12: 1176-1183 (1995) | |
| /JS/ | | WALTER, et al., "Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma," <i>Cancer Res.</i> 54: 220 (1994) | |

| | | | |
|----------------------|----------------------------------|-----------------|--|
| Examiner's Signature | /Jagdishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|-----------------------|--------------------|
| Substitute for form 1449A/PTO | | Completeness If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 1 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | "WANG, et al., "A tough biodegradable elastomer," <i>Nature Biotechnol.</i> 20: 602-606 (2002). | |
| | | WANG, et al., "Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma," <i>J. Nucl. Med.</i> 39: 1752 (1998). | |
| | | WEI, et al., "Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization," <i>Drug Delivery</i> 4: 301 (1997). | |
| | | WENIGART, et al., "Local delivery of dexamethasone in the brain for the reduction of peritumoral edema," <i>Int. J. Cancer</i> 62: 1 (1995). | |
| | | WILLIAMS, et al., "Synthetic, implantable polymers for local delivery of IUDR to experimental human malignant glioma," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 42: 63 (1998). | |
| | | WUNDERLICH, et al., "Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy," <i>Appl. Radiation Isotopes</i> 52: 63 (2000). | |
| | | YANG, et al., "Diagnostic and therapeutic potential of poly(benzyl L-glutamate)," <i>J. Pharm. Sci.</i> 83: 328 (1994). | |
| | | YAPP, et al., "Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or i.p. injection in tumor-bearing mice," <i>Anti-Cancer Drugs</i> 9: 79 (1998). | |
| | | YAPP, et al., "The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 42: 413 (1998). | |
| /JS/ | | YAPP, et al., "Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation," <i>Int. J. Radiation Oncol. Biol. Phys.</i> 39: 497 (1998). | |

| | | | |
|----------------------|-----------------------------------|-----------------|--|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|-----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|----------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Applicant Number | 10/665,793 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Edward J. Kaplan |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 13 of 13 | Attorney Docket Number | KAP 100 CIP | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| /JS/ | | YOSHIDA, et al., "In vivo release of cisplatin from a needle-type copolymer formulation implanted in rat kidney," <i>Biomaterials</i> 10: 17 (1989) | |
| /JS/ | | YUAN, et al., "Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma," <i>Radiation Oncol. Invest.</i> 7: 21 (1999) | |
| /JS/ | | *ZHANG, et al., "An all-organic actuator material with a high dielectric constant," <i>Nature</i> 419: 284-287 (2002) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|----------------------|-----------------------------------|-----------------|--|
| Examiner's Signature | /Jagadishwar Samala/ (09/24/2008) | Date Considered | |
|----------------------|-----------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1470172_v1

